← Leaderboards
Jeffrey S Miller
University Of Minnesota
$32,066,338
Attributed
$32,624,643
Total exposure
36
Grants
29
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $9.8M · FY2005–25$10M$7.5M$5M$2.5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$79,499,139 · 38
By mechanism
P01$54,339,547 · 20
P30$10,229,394 · 5
R35$8,956,287 · 2
R01$4,782,967 · 2
T32$1,116,610 · 1
M01$74,334 · 8
Top collaborators
- Gregory M Vercellotti2 shared
- Douglas Yee1 shared
Most similar at University Of Minnesota
Same institution · by research overlap
- Rachel R Hardeman$3,148,680
- Michele L Allen$11,384,036
- David H Ingbar$22,490,578
- John E Wagner$7,593,142
- Kelsey Elizabeth Johnson$1,040,824
Others in their field
Top investigators on “Natural Killer Cells”
- Barton F Haynes · Duke University$112,979,211
- Constance Ann Benson · University Of California, San Diego$65,790,143
- Gautam (george) Mitra · Leidos Biomedical Research, Inc.$53,523,213
- Craig B Thompson · Sloan-Kettering Inst Can Research$42,638,329
- Selwyn M Vickers · University Of Alabama At Birmingham$41,029,054
- James C. Paulson · Scripps Research Institute$39,353,775
Research focus
Natural Killer CellsCellsClinical TrialsFundingReceptorProgramsClinical ResearchInterleukin-15ImmuneTransplantationMalignant NeoplasmsIn VivoAdoptive TransferTumorBaseAllogenicMediatingCytomegalovirusRelapseResourcesResearch PersonnelCancer TherapySuccessGrant
Grant awards (150)
Cancer Center Support Grant$4,428,084
P30 · FY2025 · CA · contact PI
NK cells, their receptors and cancer therapy$1,853,826
P01 · FY2025 · CA · contact PI
Leadership, Planning and Evaluation$959,135
P30 · FY2025 · CA · contact PI
Targeting off-the-shelf iPSC-derived natural killer cells against solid tumors$928,524
R35 · FY2025 · CA · contact PI
Hematology Research Training Program$556,569
T32 · FY2025 · HL
Administrative and Clinical Research Support Core$440,870
P01 · FY2025 · CA · contact PI
Off-the-shelf iPSC-Derived Natural Killer Cell Immunotherapies for AML$392,480
P01 · FY2025 · CA · contact PI
Developmental Funds$286,937
P30 · FY2025 · CA · contact PI
Cancer Center Support Grant$4,078,247
P30 · FY2024 · CA · contact PI
NK cells, their receptors and cancer therapy$1,739,018
P01 · FY2024 · CA · contact PI
Targeting off-the-shelf iPSC-derived natural killer cells against solid tumors$882,098
R35 · FY2024 · CA · contact PI
Hematology Research Training Program$560,041
T32 · FY2024 · HL
Administrative and Clinical Research Support Core$390,453
P01 · FY2024 · CA · contact PI
Off-the-shelf iPSC-Derived Natural Killer Cell Immunotherapies for AML$378,249
P01 · FY2024 · CA · contact PI
NKG2C+ Adaptive NK Cells For AML$247,042
P01 · FY2024 · CA · contact PI
Support and Training for Research Independence, Diversity, and Equity (STRIDE)$200,000
P30 · FY2024 · CA · contact PI
Immunology$34,636
P30 · FY2024 · CA · contact PI
NK cells, their receptors and cancer therapy$1,804,682
P01 · FY2023 · CA · contact PI
Targeting off-the-shelf iPSC-derived natural killer cells against solid tumors$928,524
R35 · FY2023 · CA · contact PI
Off-the-shelf iPSC-Derived Natural Killer Cell Immunotherapies for AML$398,922
P01 · FY2023 · CA · contact PI
Administrative and Clinical Research Support Core$375,005
P01 · FY2023 · CA · contact PI
NKG2C+ Adaptive NK Cells For AML$263,193
P01 · FY2023 · CA · contact PI
Immunology$48,471
P30 · FY2023 · CA · contact PI
NK cells, their receptors and cancer therapy$1,753,270
P01 · FY2022 · CA · contact PI
Administrative and Clinical Research Support Core$356,590
P01 · FY2022 · CA · contact PI
NKG2C+ Adaptive NK Cells For AML$259,030
P01 · FY2022 · CA · contact PI
Immunology$48,471
P30 · FY2022 · CA · contact PI
NK cells, their receptors and cancer therapy$1,764,019
P01 · FY2021 · CA · contact PI
Viral priming and targeting NK cells against solid tumor malignancies$912,000
R35 · FY2021 · CA · contact PI
NKG2C+ Adaptive NK Cells For AML$294,004
P01 · FY2021 · CA · contact PI
Administrative and Clinical Research Support Core$294,003
P01 · FY2021 · CA · contact PI
Immunology$48,471
P30 · FY2021 · CA · contact PI
NK cells, their receptors, transplantation and cancer therapy$1,814,850
P01 · FY2020 · CA · contact PI
Viral priming and targeting NK cells against solid tumor malignancies$912,000
R35 · FY2020 · CA · contact PI
Therapeutic Potential of Adaptive NK Cells in Cancer and Transplantation$420,975
P01 · FY2020 · CA · contact PI
Administrative and Clinical Research Support Core$134,165
P01 · FY2020 · CA · contact PI
Immunology$48,471
P30 · FY2020 · CA · contact PI
NK cells, their receptors, transplantation and cancer therapy$1,761,898
P01 · FY2019 · CA · contact PI
Viral priming and targeting NK cells against solid tumor malignancies$860,921
R35 · FY2019 · CA · contact PI
Therapeutic Potential of Adaptive NK Cells in Cancer and Transplantation$408,319
P01 · FY2019 · CA · contact PI
Adaptive NK Cell Therapy to Improve UCB Transplant Outcomes$290,972
P01 · FY2019 · CA · contact PI
Administrative and Clinical Research Support Core$130,128
P01 · FY2019 · CA · contact PI
Immunology$48,471
P30 · FY2019 · CA · contact PI
NK cells, their receptors, transplantation and cancer therapy$1,814,553
P01 · FY2018 · CA · contact PI
Viral priming and targeting NK cells against solid tumor malignancies$796,220
R35 · FY2018 · CA · contact PI
Therapeutic Potential of Adaptive NK Cells in Cancer and Transplantation$386,472
P01 · FY2018 · CA · contact PI
Inducing NK cells to remember and fight cancer$382,057
R01 · FY2018 · HL · contact PI
Adaptive NK Cell Therapy to Improve UCB Transplant Outcomes$299,972
P01 · FY2018 · CA · contact PI
Administrative and Clinical Research Support Core$148,874
P01 · FY2018 · CA · contact PI
NK cells, their receptors, transplantation and cancer therapy$1,842,904
P01 · FY2017 · CA · contact PI
Viral priming and targeting NK cells against solid tumor malignancies$912,000
R35 · FY2017 · CA · contact PI
Inducing NK cells to remember and fight cancer$382,057
R01 · FY2017 · HL · contact PI
Adaptive NK Cell Therapy to Improve UCB Transplant Outcomes$299,972
P01 · FY2017 · CA · contact PI
Therapeutic Potential of Adaptive NK Cells in Cancer and Transplantation$177,059
P01 · FY2017 · CA · contact PI
Administrative and Clinical Research Support Core$58,425
P01 · FY2017 · CA · contact PI
NK cells, their receptors, transplantation and cancer therapy$1,960,158
P01 · FY2016 · CA · contact PI
Viral priming and targeting NK cells against solid tumor malignancies$912,000
R35 · FY2016 · CA · contact PI
Therapeutic Potential of Adaptive NK Cells in Cancer and Transplantation$432,822
P01 · FY2016 · CA · contact PI
Inducing NK cells to remember and fight cancer$383,822
R01 · FY2016 · HL · contact PI
Adaptive NK Cell Therapy to Improve UCB Transplant Outcomes$299,972
P01 · FY2016 · CA · contact PI
Administrative and Clinical Research Support Core$145,532
P01 · FY2016 · CA · contact PI
Program Integration and Management$7,429
P01 · FY2016 · CA · contact PI
Viral priming and targeting NK cells against solid tumor malignancies$912,000
R35 · FY2015 · CA · contact PI
Inducing NK cells to remember and fight cancer$393,292
R01 · FY2015 · HL · contact PI
Adaptive NK Cell Therapy to Improve UCB Transplant Outcomes$302,076
P01 · FY2015 · CA · contact PI
NK cells, their receptors and unrelated donor transplant$2,074,355
P01 · FY2014 · CA · contact PI
NK Cells and Their Receptor in Leukemia Therapy$311,471
P01 · FY2014 · CA · contact PI
Cell Therapy and Monitoring Core$310,405
P01 · FY2014 · CA · contact PI
NK Cell Education in Recipients of Allogeneic HCT$276,609
P01 · FY2014 · CA · contact PI
Administrative and Clinical Research Support Core$204,611
P01 · FY2014 · CA · contact PI
NK cells, their receptors and unrelated donor transplant$1,815,760
P01 · FY2013 · CA · contact PI
NK Cells and Their Receptor in Leukemia Therapy$332,372
P01 · FY2013 · CA · contact PI
Cell Therapy and Monitoring Core$330,088
P01 · FY2013 · CA · contact PI
NK Cell Education in Recipients of Allogeneic HCT$259,578
P01 · FY2013 · CA · contact PI
Administrative and Clinical Research Support Core$186,769
P01 · FY2013 · CA · contact PI
NK cells, their receptors and unrelated donor transplant$1,937,144
P01 · FY2012 · CA · contact PI
Cell Therapy and Monitoring Core$325,304
P01 · FY2012 · CA · contact PI
NK Cells and Their Receptor in Leukemia Therapy$305,687
P01 · FY2012 · CA · contact PI
NK Cell Education in Recipients of Allogeneic HCT$277,637
P01 · FY2012 · CA · contact PI
Administrative and Clinical Research Support Core$206,218
P01 · FY2012 · CA · contact PI
Cell Therapy and Monitoring Core$9,296
P01 · FY2012 · CA · contact PI
NK Cells and Their Receptor in Leukemia Therapy$9,296
P01 · FY2012 · CA · contact PI
NK cells, their receptors and unrelated donor transplant$1,944,102
P01 · FY2011 · CA · contact PI
Cell Therapy and Monitoring Core$325,917
P01 · FY2011 · CA · contact PI
NK Cells and Their Receptor in Leukemia Therapy$307,622
P01 · FY2011 · CA · contact PI
NK Cell Education in Recipients of Allogeneic HCT$225,098
P01 · FY2011 · CA · contact PI
Administrative and Clinical Research Support Core$155,038
P01 · FY2011 · CA · contact PI
NK cells, their receptors and unrelated donor transplant$2,060,530
P01 · FY2010 · CA · contact PI
NK Cell Differentiation from Stem Cells$377,500
R01 · FY2010 · HL · contact PI
Cell Therapy and Monitoring Core$229,059
P01 · FY2010 · CA · contact PI
NK Cell Education in Recipients of Allogeneic HCT$227,634
P01 · FY2010 · CA · contact PI
NK Cells and Their Receptor in Leukemia Therapy$210,583
P01 · FY2010 · CA · contact PI
Administrative and Clinical Research Support Core$161,134
P01 · FY2010 · CA · contact PI
NK Cells, Their Receptors and Unrelated Donor Transplant$2,105,144
P01 · FY2009 · CA · contact PI
NK Cell Differentiation from Stem Cells$377,500
R01 · FY2009 · HL · contact PI
Acquisition of KIR in Recipients of Unrelated Donor HCT$246,590
P01 · FY2009 · CA · contact PI
Public KIR Database$95,847
P01 · FY2009 · CA · contact PI
NK Cells, Their Receptors and Unrelated Donor Transplant$1,990,871
P01 · FY2008 · CA · contact PI
Lymphoid Differentiation from Stem Cells$281,609
R01 · FY2008 · HL · contact PI
Acquisition of KIR in Recipients of Unrelated Donor HCT$242,877
P01 · FY2008 · CA · contact PI
Public KIR Database$94,016
P01 · FY2008 · CA · contact PI
Core--Cell processing$87,718
P01 · FY2008 · HD · contact PI
MT2005-18: TRANSPLANTATION OF UMBILICAL CORD BLOOD FOR MYELOID LEUKEMIA PATIENTS$17,227
M01 · FY2008 · RR · contact PI
CLINICAL TRIAL: MT2004-25: ALLOGENEIC NATURAL KILLER CELLS WITH RELAPSED ACUTE M$16,895
M01 · FY2008 · RR · contact PI
NK Cells, Their Receptors and Unrelated Donor Transplant$1,977,850
P01 · FY2007 · CA · contact PI
Lymphoid Differentiation from Stem Cells$281,609
R01 · FY2007 · HL · contact PI
Acquisition of KIR in Recipients of Unrelated Donor HCT$241,647
P01 · FY2007 · CA · contact PI
Public KIR Database$93,140
P01 · FY2007 · CA · contact PI
Core--Cell processing$86,903
P01 · FY2007 · HD · contact PI
MT2004-25: ALLOGENEIC NATURAL KILLER CELLS WITH RELAPSED ACUTE MYELOGENOUS LEUKE$21,228
M01 · FY2007 · RR · contact PI
MT2005-18: TRANSPLANTATION OF UMBILICAL CORD BLOOD FOR MYELOID LEUKEMIA PATIENTS$17,338
M01 · FY2007 · RR · contact PI
MT1999-06-VACCINATION WITH TETANUS AND KLH TO ASSESS IMMUNE RESPONSES$1,646
M01 · FY2007 · RR · contact PI
NK Cells, Their Receptors and Unrelated Donor Transplant$1,985,078
P01 · FY2006 · CA · contact PI
Lymphoid Differentiation from Stem Cells$290,021
R01 · FY2006 · HL · contact PI
NK Cells and Their Receptors in Leukemia Therapy$214,967
P01 · FY2006 · CA · contact PI
Acquisition of KIR in Recipients of Unrelated Donor HCT$186,269
P01 · FY2006 · CA · contact PI
Core--Cell processing$82,330
P01 · FY2006 · HD · contact PI
Public KIR Database$71,482
P01 · FY2006 · CA · contact PI
NK Cells, Their Receptors and Unrelated Donor Transplant$2,168,153
P01 · FY2005 · CA
Cell Therapy and Monitoring Core$412,017
P01 · FY2005 · CA
Lymphoid Differentiation from Stem Cells$297,000
R01 · FY2005 · HL
NK Cells and Their Receptors in Leukemia Therapy$208,898
P01 · FY2005 · CA
Acquisition of KIR in Recipients of Unrelated Donor HCT$204,672
P01 · FY2005 · CA
Administrative Core$144,478
P01 · FY2005 · CA
Core--Cell processing$79,932
P01 · FY2005 · HD
Public KIR Database$79,563
P01 · FY2005 · CA
Lymphoid Differentiation from Stem Cells$297,000
R01 · FY2004 · HL
Core--Cell processing$77,605
P01 · FY2004 · HD
LYMPHOID DIFFERENTIATION FROM STEM CELLS$259,875
R01 · FY2003 · HL
LYMPHOID DIFFERENTIATION FROM STEM CELLS$259,875
R01 · FY2002 · HL
EFFECTS OF BCR/ABL ON NATURAL KILLER CELLS IN CML$0
P01 · FY2002 · CA
CORE--CELL THERAPY AND MONITORING FACILITY$0
P01 · FY2002 · CA
VACCINATION WITH TETANUS AND KLH TO ASSESS IMMUNE RESPONSES$0
M01 · FY2002 · RR
VACCINATION WITH TETANUS AND KLH TO ASSESS IMMUNE RESPONSES$0
M01 · FY2002 · RR
NORMAL DONOR BONE MARROW /PERIPHERAL BLOOD FOR LABORATORY RESEARCH$0
M01 · FY2002 · RR
NORMAL DONOR BONE MARROW /PERIPHERAL BLOOD FOR LABORATORY RESEARCH$0
M01 · FY2002 · RR
IMMUNOTHERAPY AFTER AUTOLOGOUS STEM CELL TRANSPLANT TO PREVENT RELAPSE$0
M01 · FY2002 · RR
IMMUNOTHERAPY AFTER AUTOLOGOUS STEM CELL TRANSPLANT TO PREVENT RELAPSE$0
M01 · FY2002 · RR
LYMPHOID DIFFERENTIATION FROM STEM CELLS$259,875
R01 · FY2001 · HL
CORE--CELL THERAPY AND MONITORING FACILITY$0
P01 · FY2001 · CA
EFFECTS OF BCR/ABL ON NATURAL KILLER CELLS IN CML$0
P01 · FY2001 · CA
VACCINATION WITH TETANUS AND KLH TO ASSESS IMMUNE RESPONSES$0
M01 · FY2001 · RR
NORMAL DONOR BONE MARROW /PERIPHERAL BLOOD FOR LABORATORY RESEARCH$0
M01 · FY2001 · RR
IMMUNOTHERAPY AFTER AUTOLOGOUS STEM CELL TRANSPLANT TO PREVENT RELAPSE$0
M01 · FY2001 · RR
LYMPHOID DIFFERENTIATION FROM STEM CELLS$259,875
R01 · FY2000 · HL
CORE--CELL THERAPY AND MONITORING FACILITY$0
P01 · FY2000 · CA
EFFECTS OF BCR/ABL ON NATURAL KILLER CELLS IN CML$0
P01 · FY2000 · CA
VACCINATION WITH TETANUS AND KLH TO ASSESS IMMUNE RESPONSES$0
M01 · FY2000 · RR
NORMAL DONOR BONE MARROW /PERIPHERAL BLOOD FOR LABORATORY RESEARCH$0
M01 · FY2000 · RR
IMMUNOTHERAPY AFTER AUTOLOGOUS STEM CELL TRANSPLANT TO PREVENT RELAPSE$0
M01 · FY2000 · RR